My solution for air pollution. What do u think?
Solve CoLab is a forum in which individuals and groups collaborate on solutions to global challenges.
Read more
ExoMars will soon start aerobraking in Mars orbit in a years-long effort to sample Mars super-thin lower atmosphere in the ongoing search for trace gases indicative of life and active geology.
ESA’s ExoMars Trace Gas Orbiter is preparing to aerobrake into parts of the unexplored Martian lower atmosphere in search of methane, water vapor and other possible signatures of life on the Red Planet.
Read more
New study provides deeper insight into the immune system.
In a bid to better understand the gene expression patterns that control T cell activity, researchers at the La Jolla Institute for Allergy and Immunology mapped genome-wide changes in chromatin accessibility as T cells respond to acute and chronic virus infections. Their findings, published in the Dec. 20, 2016 issue of Immunity, shed light on the molecular mechanisms that determine the fate of T lymphocytes and open new approaches to clinical intervention strategies to modulate T cell activity and improve immune function.
“Identifying the different factors that determine different T cell states and therefore their function helps us understand if T cells will be able or not to fight viral infections or tumor growth, and if they will be able or not to provide long-term protection,” says the study’s first author James Scott-Browne, a postdoctoral fellow in the laboratory of Anjana Rao, a professor in the Division of Signaling and Gene Expression. “We may be able to revert the exhaustion phenotype of T cells and render them better able to fight tumors or chronic viral infections such as HIV, or generate better memory cells in response to vaccines.”
When viruses invade or cells turn malignant, the immune system mobilizes a small cohort of naïve or immature CD8 T cells, a crucial subdivision of the immune system charged with killing virus-infected and cancerous cells. Upon activation, they mature and proliferate exponentially into highly specific effector T cells that eliminate virus-infected or otherwise compromised cells. After their job is done, most effector T cells die leaving behind only a small contingent of memory T cell that confer long-term protection.
Read more
Stanford University’s amazing new regenerative medicine facility where the impossible is becoming possible.
The 25,000-square-foot facility, which opened last September, puts Stanford at the forefront of one of medicine’s most important and promising trends: regenerative medicine, which aims to refurbish diseased or damaged tissue using the body’s own healthy cells.
“We’re curing the incurable,” said laboratory director David DiGiusto, who holds a doctorate.
Critics complain that no one makes anything in Silicon Valley anymore except mobile apps and plug-in cars, a decades-long gripe that dates back to the shuttering of chip fabrication plants.
Smile Vector is a Twitter bot that can make any celebrity smile. It scrapes the web for pictures of faces, and then it morphs their expressions using a deep-learning-powered neural network. Its results aren’t perfect, but they’re created completely automatically, and it’s just a small hint of what’s to come as artificial intelligence opens a new world of image, audio, and video fakery. Imagine a version of Photoshop that can edit an image as easily as you can edit a Word document — will we ever trust our own eyes again?
Read more
Decline of the immune system is one of the areas SENS are working on, with just over a week left for the Winter Fundraiser and Triple donation match now is the time to support their work!
Immunosenescence is a key process in aging and rejuvention or replacement of the thymus which gradually wastes away as we age exposing us to pathogens is an important step in dealing with age-related diseases. SENS is working on these problems so if you want to see solutions please consider donating to our Winter Fundraiser today on the link below:
“As we age and are exposed to persistent pathogens, especially cytomegalovirus, ever more of the T cell population becomes specialized in ways that remove the ability to deal with new threats. A flood of new immune cells would help to restore the balance, and in recent years researchers have demonstrated that transplanting a young and active thymus into an old mouse does in fact restore measures of immune function, and extends life span as well.”
Light therapy kills cancer in new no surgery, no chemo approach.
A new non-surgical treatment for low-risk prostate cancer can effectively kill cancer cells while preserving healthy tissue, reports a new UCL-led phase III clinical trial in 413 patients. The trial was funded by STEBA Biotech which holds the commercial license for the treatment.
The new treatment, ‘vascular-targeted photodynamic therapy’ (VTP), involves injecting a light-sensitive drug into the bloodstream and then activating it with a laser to destroy tumour tissue in the prostate. The research, published in The Lancet Oncology, found that around half (49%) of patients treated with VTP went into complete remission compared with 13.5% in the control group.
“These results are excellent news for men with early localised prostate cancer, offering a treatment that can kill cancer without removing or destroying the prostate,” says lead investigator Professor Mark Emberton, Dean of UCL Medical Sciences and Consultant Urologist at UCLH. “This is truly a huge leap forward for prostate cancer treatment, which has previously lagged decades behind other solid cancers such as breast cancer. In 1975 almost everyone with breast cancer was given a radical mastectomy, but since then treatments have steady improved and we now rarely need to remove the whole breast. In prostate cancer we are still commonly removing or irradiating the whole prostate, so the success of this new tissue-preserving treatment is welcome news indeed.”
The biotech battle between China and the US has begun as we predicated when we announced the first CRISPR deployment in humans last month. The US has upped the ante and is taking a step further in the race for the biotech crown. All great news for us as the more competition the faster progress will move so let’s hope there is a fierce battle for biotech coming.
In 2015, a little girl called Layla was treated with gene-edited immune cells that eliminated all signs of the leukemia that was killing her. Layla’s treatment was a one-off, but by the end of 2017, the technique could have saved dozens of lives.
It took many years to develop the gene-editing tool that saved Layla, but thanks to a revolutionary method known as CRISPR, this can now be done in just weeks.
In fact, CRISPR works so well that the first human trial involving the method has already begun. In China, it is being used to disable a gene called PD-1 in immune cells taken from individuals with cancer. The edited cells are then injected back into each person’s body.